WO2005007834A1 - Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus - Google Patents
Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus Download PDFInfo
- Publication number
- WO2005007834A1 WO2005007834A1 PCT/KR2003/001461 KR0301461W WO2005007834A1 WO 2005007834 A1 WO2005007834 A1 WO 2005007834A1 KR 0301461 W KR0301461 W KR 0301461W WO 2005007834 A1 WO2005007834 A1 WO 2005007834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probio
- coronavirus
- lactobacillus plantarum
- growth
- present
- Prior art date
Links
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 35
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 6
- 240000006024 Lactobacillus plantarum Species 0.000 title claims description 46
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims description 46
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims description 46
- 239000006041 probiotic Substances 0.000 title abstract description 33
- 235000018291 probiotics Nutrition 0.000 title abstract description 33
- 244000000010 microbial pathogen Species 0.000 title abstract description 3
- 239000002253 acid Substances 0.000 title description 14
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 241000186660 Lactobacillus Species 0.000 claims abstract description 9
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 206010012735 Diarrhoea Diseases 0.000 claims description 14
- 210000000936 intestine Anatomy 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000000273 veterinary drug Substances 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 16
- 239000003613 bile acid Substances 0.000 abstract description 16
- 244000000021 enteric pathogen Species 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 241000004176 Alphacoronavirus Species 0.000 description 29
- 229960005486 vaccine Drugs 0.000 description 14
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 230000003115 biocidal effect Effects 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 244000144972 livestock Species 0.000 description 10
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000006916 nutrient agar Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 208000005577 Gastroenteritis Diseases 0.000 description 5
- 241000186610 Lactobacillus sp. Species 0.000 description 5
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000588919 Citrobacter freundii Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241001106597 Enterococcus lactis Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 2
- 244000292604 Salvia columbariae Species 0.000 description 2
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 2
- 235000001498 Salvia hispanica Nutrition 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 235000014167 chia Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000004229 gastric stump Anatomy 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 229940040511 liver extract Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000191953 Kocuria varians Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000191936 Micrococcus sp. Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 241000191973 Staphylococcus xylosus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates to a novel Lactobacillus plantarum Probio-38 having the inhibition activity against porcine transmissible gastroenteritis (hereinafter, referred to as "TGE") Coronavirus and other pathogenic microbes and probiotics comprising the same. More particularly the present invention relates to Lactobacillus plantarum Probio-38 that is separated from pig's stomach, is tolerant of acid and bile acid, resistant to antibiotics and can suppress the growth of TGE Coronavirus and enteric pathogens effectively, probiotics comprising the same and methods for preventing and treating livestock' diarrhea by using the same.
- TGE porcine transmissible gastroenteritis
- TGE Transmissible gastroenteritis
- TGE is so severe disease as a sort of diarrhea to kill 80 ⁇ 90% of lactivorous pigs and more than 20% of pigs, to decrease the appetite of hogs and boars and to suppress the growth of swine.
- TGE is caused by Coronavirus that inhabits hog raising farm and natural environment and actually, becomes more harmful through the secondary infection of Escherichia coli.
- this diarrhea against Coronavirus cannot be remedied easily by using an antibiotic since it is a viral disease.
- the antibiotic is expected only to treat the secondary infection of microbes. On the other hand, it is a global trend to avoid the antibiotic abuse.
- Coronavirus vaccine has been utilized to prevent the infection of porcine TGE Coronavirus, but there is also a problem that this vaccine may have some side effects.
- various microbes exist and form normal intestinal flora.
- some of microbes such as Lactobacillus sp. are known to be useful for host animals.
- other microbes such as Esche chia coli, Salmonella sp., Staphylococcus sp. and the like are harmful directly or potentially for host cells.
- the intestinal flora of normal microbes may be destructed if stress is increased, pathogenic bacteria are infected and outer environment is changed in human and animals. Therefore, the harmful microbes can proliferate rapidly, aggravates the health condition of host animal and become dangerous to cause diarrhea and even death.
- the antibiotic is administered for therapeutic purpose, but it is not discharged completely after use and sustained within the body. Hence, if the antibiotic continued to be injected, the pathogenic microbes become resistant to drugs and will not be treated easily. In the meantime, the antibiotic content is strictly regulated in meat, milk, eggs and the like produced from livestock. Therefore, it is necessary to think over the use and abuse of antibiotics again.
- Probiotic as a live vaccine is manufactured to pharmaceutical composition for commercial use, after useful microbes are separated from the intestine of human and animal.
- aerobic bacteria, anaerobic bacteria, lactobacillus, yeast and the like can be exploited and especially, Lactobacillus sp. is widely adopted.
- Lactobacillus sp. has been utilized to ferment and process traditional food and is proved to be safe for a long time.
- several strains of Lactobacillus sp. have been already disclosed in GRAS (generally recognized as safe) list according to FDA standard.
- the probiotic comprising Lactobacillus strain, causes no side effect, can suppress the abnormal fermentation of enteric pathogens, sustain the intestinal flora stably and reduce the infection of harmful microbe. Furthermore, it can increase the fodder efficiency as a live vaccine if continued to be administered, enhance the health condition and maximize the body weight of livestock.
- the probiotic should be tolerant of acid and bile acid as well as suppress the growth of pathogenic microbes. Precisely, the live vaccine meets the strong acid of gastric juice after administered until reaching the intestine and afterward confronts bile acids.
- the present inventors have attempted to screen novel live vaccine that can suppress the growth of pathogenic microbes more effectively than conventional live vaccines, be tolerant of acid and bile acid and specifically suppress the growth of porcine TGE Coronavirus.
- an intestinal microbe that have the inhibition activity against pathogenic microbes, is highly resistant to acid and bile acids and suppresses the growth of porcine TGE Coronavirus effectively, from pig's stomach in an anaerobic condition and examined.
- the present inventors have identified the microbe as Lactobacillus plantarum and completed the present invention successfully.
- the object of the present invention is to provide a novel microbe that is harmless for human and animal and is tolerant of acid and bile acids remarkably.
- Another object of the present invention is to provide compositions comprising the probiotic microbe, which can replace conventional antibiotics and suppress the growth of Coronavirus and pathogenic microbes in intestine, when it is administered to livestock and used as pharmaceuticals, fodder additive, veterinary drug or the like.
- Another object of the present invention is to provide a method for suppressing Coronavirus or for preventing and/or treating disease caused by the virus, in which the microbe of the present invention or the compositions comprising the same is utilized.
- the other object of the present invention is to provide a method for suppressing the growth of enteric pathogens or for preventing and/or treating disease caused by the pathogenic microbes, in which the microbe of the present invention is utilized.
- FIG. 1 depicts the nucleotide sequence of 16S rRNA gene separated from Lactobacillus plantarum Probio-38 (accession number: KCCM-10329) of the present invention.
- the present inventors have tried to provide a novel strain, Lactobacillus plantarum Probio-38 that can suppress the growth of porcine TGE Coronavirus and other enteric pathogens and is tolerant of acid and bile acid, probiotic compositions comprising the same such as food, pharmaceuticals, veterinary drug, fodder additive or the like and a method for suppressing the growth of porcine TGE Coronavirus and enteric pathogens in which Lactobacillus plantarum Probio-38 strain is used.
- Lactobacillus plantarum Probio-38 of the present invention is an enteric microbe derived from pig's stomach and is elucidated to survive in an anaerobic condition, to suppress the growth of porcine TGE Coronavirus and other harmful microbes and as a result, to prevent and treat livestock' diarrhea efficiently.
- the present inventors have already developed and modified the method for preventing or treating diarrhea caused by Coronavirus infection.
- the attenuated vaccine of porcine epidemic diarrhea virus is commercially available to treat porcine diarrhea caused by TGE Coronavirus.
- this vaccine is not utilized widely, since it is not promoted around domestic fields and due to the poor environment of hog raising farms and thus, TGE Coronavirus has not been eradicated yet.
- the present invention provides an effective and potential probiotic that can treat diarrhea and/or gastroenteritis caused by the infection of porcine Coronavirus and other pathogenic microbes in intestine. Therefore, the probiotic microbe of the present invention can be
- microbes that inhabit in food such as fodder and on livestock' intestine.
- the microbe of the present invention can adsorb onto intestinal
- Capacity to suppress the growth of porcine Coronavirus and other enteric pathogenic microbes Capacity to grow both in aerobic and an anaerobic condition and to grow in the wide range of pH; which can adjust the microbe to the physiological and pathological changes in stomach Tolerance to acid and bile acid Capacity to sustain the activity of live vaccine after lyophilized
- novel microbe of the present invention has a
- probiotic means "a living microbe which improves the enteric microbial
- probiotic activity and manufactured to single or complex form can confer a beneficial effect upon the intestinal flora of host animal, when it is administered in the state of dried cell or fermented product for human or animal.
- "porcine Coronavirus” defines "a major viral contagion derived from pigs", and includes porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and the like. It occurs even in domestic area every year and damages the hog raising industry enormously. Especially, the microbe of the present invention is outstanding to suppress the growth of TGEV. TGEV is highly transmissible, causes vomiting and severe diarrhea and is sensitive to all the swine regardless of age.
- TGEV causes most severe diarrhea to newborn pigs under 2-weeked age and increases the fatality rate highly. It may infect and destruct cells on small intestine selectively so as to prevent the nutrient absorption and the regulation of body fluid (H. W. Moon, J. Am. Vet. Med. Assoc, 172, 443, 1978).
- the present inventors have tried to screen the probiotic microbe that can suppress the growth of porcine TGE Coronavirus and enteric pathogenic microbes and is tolerant of acid and bile acids through the procedure as follows. That is to say, gastric remnant 30 g is collected from pigs, poured to an anaerobic bag (commercial name, Gas Pack pouch; purchased from BBL Co.
- GAM semi-agar plate purchased from llsu
- coli KCTC 2571 Klebsiella pneumoniae KCTC 2208, Staphylococcus aureus KCTC 1621 , Staphylococcus epidermidis KCTC 1917, Salmonella entehtidis, Shigella flexneri KCTC 2008, Salmonella gallinarum, Enterobacter cloacea KCTC 2361, Enterococcus lactis KCTC 1913, Salmonella typhimurium, Citrobacter freundii KCTC 2006 and Bacillus subtilis KCTC 1021.
- NA nutrient agar
- Lactobacillus plantarum of the present invention is cultivated anaerobically in MRS culture broth at
- Lactobacillus plantarum Probio-38 one strain that can suppress the growth of pathogenic microbes most outstandingly are selected and named as Lactobacillus plantarum Probio-38.
- Probio-38 strain is examined to elucidate morphological, physiological and biochemical characteristics, to determine the nucleotide sequence of 16S rRNA gene, and to analyze the sequence. Consequently, it is identified that Probio-38 strain is a Gram- positive bacterium, can proliferate both in aerobic and anaerobic conditions, does not make spores, has no mobility and has the bacillus
- Probio-38 strain is preferable to proliferate at 30 ⁇ 37°C, does not
- the nucleotide sequence of 16S rRNA gene from Probio-38 strain of the present invention contains the nucleotide sequence of SEQ ID NO: 1 as illustrated in FIG. 1.
- Probio-38 strain is further investigated through the molecular phylogenic analysis based upon the nucleotide sequence of 16S rRNA. Therefore, Probio-38 strain of the present invention is identified to belong to Bacillus sp., to have 99.5% of 16S rDNA homology and to have the highest phylogenic relationship with the standard strain of Lactobacillus plantarum.
- the Probio-38 strain of the present invention is named as Lactobacillus plantarum Probio-38 and has been deposited to Korean Culture Center of Microorganism, Korea Federation of Culture Collections (International Deposition Organization; Yoorim B/D FL 2, 361-221 Hongje-Dong, Seodaemoon-Gu, Seoul, Korea) as accession number KCCM-10329 on October 27, 2001.
- Lactobacillus plantarum Probio-38 of the present invention is named as Lactobacillus plantarum Probio-38 and has been deposited to Korean Culture Center of Microorganism, Korea Federation of Culture Collections (International Deposition Organization; Yoorim B/D FL 2, 361-221 Hongje-Dong, Seodaemoon-Gu, Seoul, Korea) as accession number KCCM-10329 on October 27, 2001.
- invention can be submerged in glycerol at -80°C or lyophilized after
- the probiotic strain of the present invention can be improved or modified through conventional physiochemical methods, such as mutagenesis to enhance the stability or the antiviral activity.
- the probiotic strain of the present invention is examined whether it can suppress the growth of TGE Coronavirus or not. As a result, it is confirmed to have the antiviral activity against Coronavirus since cytopathic effect is not observed.
- the probiotic strain is investigated whether it can be sensitive to antibiotics or not. As a result, it is verified to have the inhibition activity against enteric pathogens in the stomach and to be resistant to various kinds of veterinary antibiotics.
- the probiotic strain of the present invention is more advantageous to raise livestock since it is separated from pig's stomach and makes the normal flora of enteric microbes as demonstrated above.
- the present invention provides food, pharmaceuticals, veterinary drug or fodder additive comprising Lactobacillus plantarum Probio-38 strain.
- the probiotic microbe of the present invention can be prepared with pharmaceutically acceptable carrier, utilized independently or as a food additive and manufactured to compositions suitable for human and animal. Namely, the microbe of the present invention can be added to food without other probiotic microbe (conferring the probiotic activity, if added) and/or food with several probiotic microbes (enhancing or compensating the probiotic activity, if added) before use.
- the pharmaceutical, veterinary or nutritional composition of the present invention can be composed of Lactobacillus plantarum Probio-38 strain as a probiotic microbe or additionally composed of more than 2 kinds of another useful strains and acceptable carriers.
- the strain that is compatible with Lactobacillus plantarum Probio-38 to prepare the compositions of the present invention should be edible for animal, suppress the proliferation of virus or pathogenic microbes and improve the microbial balance of mammal's intestine, in addition to the probiotic activity.
- yeast such as Saccharomyces, Candida, Pichia, Torulopsis and the like
- fungi such as Aspergillus, Rhizopus, Mucor, Penicillium and the like
- bacteria such as Lactobacillus, Bifidobacte um, Clostridium, Leuconostoc, Bacteroides, Staphylococcus, Lactococcus, Bacillus, Streptococcus, Fusobactehum, Propionibacterium, Enterococcus, Pediococcus, and Micrococcus sp.
- yeast such as Saccharomyces, Candida, Pichia, Torulopsis and the like
- fungi such as Aspergillus, Rhizopus, Mucor, Penicillium and the like
- bacteria such as Lactobacillus, Bifidobacte um, Clostridium, Leuconostoc, Bacteroides, Staphylococcus, Lactococcus, Bacillus,
- the strain can be selected among Saccharomyces cereviseae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobactehum infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbruckii, Lactobacillus johnsonii, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus sake, Lactococcus lactis, Micrococcus varians, Pediococcus acidilactici, Staphylococcus, Bac
- Lactobacillus reuteri Probio-16 (accession number: KCCM 10214) that can suppress the growth of Rotavirus causing porcine diarrhea as well as has the probiotic activity and Lactobacillus salibarius Probio-37 (accession number: KCCM 10328) that can suppress the growth of Coronavirus or their microbial mixture, can be added to the compositions of the present invention.
- the composition of the present invention can include one more acceptable carrier selected among weight-increase agent, polymer additive, capsules, lipid and the like. These carriers are disclosed clearly to those skilled in the art.
- Lactobacillus plantarum Probio-38 of the present invention can be lyophilized or made to a capsule, culture suspension or dry powder.
- the microbe and the compositions of the present invention can be administered to animals directly or coordinately with food, pharmaceuticals, veterinary drug or fodder additive as a probiotic agent.
- the probiotic agent aims to replace the existed antibiotics, to suppress the growth of enteric pathogens in human and various livestock, to sustain the intestinal flora stably, to make the animal body healthier, to increase the weight of livestock, to improve the quality of meat, to increase the productivity of milk and to enhance the immunity and the like.
- the probiotic composition of the present invention can be treated even after the antibiotic is already injected.
- the microbe of the present invention also has the antiviral activity and is used to alleviate and treat most symptoms caused by Coronavirus infection, when other treatment is not effective and has the side effect on clinical use. Therefore, the present invention provides the method for preventing the Coronavirus infection or for treating gastroenteritis, diarrhea and the like caused by Coronavirus, by using the probiotic strain and the compositions comprising the same. Also, the present invention provides the method for suppressing the growth of enteric pathogenic microbes or for treating gastroenteritis, diarrhea and the like caused by the pathogens.
- Gastric remnant from normal pig was collected to an anaerobic bag (commercial name, Gas Pack pouch; a product from BBL Co. Ltd.), moved in the anaerobic condition and examined. 30 g of the resulting remnant collected above was diluted to 1 : 10 ratio by using 270 ml of
- horse serum 50m£ were dissolved in distilled water 1,000ml. and then
- agar 15 g was added; solution A, 10% KH 2 P0 4 and 10% K 2 HP0 4 and solution B, magnesium sulfate 10 g, iron sulfate 0.5 g, salt 0.5 g and
- GAM semi-agar plate purchased from llsu Pharmaceutics, Japan
- peptone 10 g Soya peptone 3 g, proteose peptone No.3 10 g, peptonized whale serum 13.5 g
- yeast extract 5 g beef extract 2.2 g
- liver extract 1.2 g KH 2 P0 4 2.5 g
- NaCI 3 g L-cystein 0.3 g
- sodium thioglycolate 0.3 g and glucose 2 g were dissolved in
- Probio-38 strain separated in Example 1 was cultivated on MRS
- Probio-38 strain the morphological and physiological properties were examined through the method of Yoon et al. and by using API 32A kit and CHL kit (purchased from Biomerieux Co. Ltd.)(Yoon et al., Int. J. Syst Bactehol., 47, 904, 1997).
- the nucleotide sequence of 16S rRNA gene was determined and analyzed by performing the method of Yoon et al. (Yoon et al., Int. J. Syst. Bactehol., 47, 933, 1997).
- the morphological, physiological and biochemical characteristics of Probio-38 strain are illustrated in Table 1. ⁇ Table 1 > Morphological, physiological and biochemical characteristics of Probio-38 strain
- Probio-38 strain is a Gram-positive bacterium, can proliferate both in aerobic and anaerobic conditions, does not make spores, have no mobility and be a bacillus in the shape.
- Probio-38 strain is preferable to grow at 30 ⁇ 37°C, does not generate gas and indoles, does not induce hemolysis, not reduce nitric acid and is tolerant of bile acid 0.5%.
- the nucleotide sequence of 16S rRNA gene purified from Probio- 38 strain of the present invention is illustrated in FIG. 1. Probio-38 strain was investigated through the molecular phylogenic analysis, based upon the nucleotide sequence of 16S rRNA.
- Probio-38 strain of the present invention is verified to belong to Bacillus sp., to have 99.5% sequence homology of 16S rDNA and to have the highest phylogenic relationship with the standard strain of Lactobacillus plantarum.
- Probio-38 strain of the present invention was named as Lactobacillus plantarum Probio-38 and has been deposited to Korean Culture Center of Microorganism, International Deposition Organization on October 27, 2001 (accession number KCCM-10329).
- TGE virus strain and ST cell were prepared in the Example.
- Virus culture TGE virus strain was inoculated onto ST cell monolayer, adsorbed on cell for about 30 minutes, mixed with fresh Eagle's minimum essential medium (MEM) containing 5% bovine serum in a
- CPE cytopathic effect
- Virus titration ST cell monolayer was prepared on 96-well culture plate and TGE virus was diluted through 10-fold serial dilution. Then, each virus aliquot was poured to 10 wells of culture plate respectively and
- the virus titer of the culture medium was estimated according to Reed and Muench method.
- ST cell monolayer was prepared onto 96-well culture plate and 90 ⁇ l of virus titer 10.0 TCID 5 o/0.1m£, 100 TCID 50 /0J ⁇ and 1000 TCID 5 o/OJm£ were poured to the first, the second and the third wells independently.
- 10m (10%) culture medium of Lactobacillus plantarum Probio-38 was poured to each well and cultivated at 37°C with a incubator containing 5% C0 2 so as to measure CPE after 24, 48 and 72 hours lapsed.
- the culture medium of Lactobacillus plantarum Probio-38 was verified not to have the antiviral activity when the cytopathic effect (CPE) was observed.
- the inhibition activity against Coronavirus in Lactobacillus plantarum Probio- 38 is illustrated in Table 2.
- coli KCTC 2571 Klebsiella pneumoniae KCTC 2208, Staphylococcus aureus KCTC 1621 , Staphylococcus epidermidis KCTC 1917, Salmonella ente tidis, Shigella flexneri KCTC 2008, Salmonella gallinarum, Enterobacter cloacea KCTC 2361 , Enterococcus lactis KCTC 1913, Salmonella typhimuhum, Citrobacter freundii KCTC 2006 and Bacillus subtilis KCTC 1021.
- the pathogenic microbes described above were cultivated in NB (nutrient broth) medium at 37°C for 18 hours. Then 10 mi of the culture medium was smeared on
- Lactobacillus plantarum of the present invention was cultivated in an anaerobic condition by using MRS culture broth at 37°C for 18 hours. Again, 30 ⁇ l of culture medium was inoculated on 8 mm paper disc placed on the above-mentioned NA plate and cultivated at 37°C for 24 hours. Afterward, the clear zone was measured to compare that of standard group. As a result, one strain was selected to suppress the growth of pathogenic microbes most outstandingly and named as Lactobacillus plantarum Probio-38. The inhibition activity against pathogenic microbes is illustrated in Table 3. ⁇ Table 3> Inhibition activity against pathogenic microbes by Lactobacillus plantarum Probio-38
- Lactobacillus plantarum Probio-38 suppress the growth of almost 13 pathogenic microbes and be a useful probiotic microbe.
- Lactobacillus plantarum Probio-38 was utilized according to the protocol of Becton Dickinson Microbiology Systems.
- 11 kinds of antibiotics were adopted as follows: tetracycline, ampicillin, gentamicin, cephalothin, sulfisoxazole, carbenicillin, streptomycin, lincomycin, neomycin, penicillin and erythromycin.
- Lactobacillus plantarum Probio-38 of the present invention was cultivated in MRS culture broth at 37°C for 18 hours and smeared homogeneously on MRS culture plate.
- Lactobacillus plantarum Probio-38 is highly sensitive to ampicillin, carbenicillin and erythromycin.
- the novel microbe of the present invention separated from pig's intestine, Lactobacillus plantarum Probio-38 can suppress the growth of TGE Coronavirus and other pathogenic microbes effectively and is tolerant of acid and bile acid. Therefore instead of conventional antibiotics, the microbe and the compositions of the present invention can be administered for human and animals to make the animal body healthier, to increase the weight of livestock, to improve the quality of meat, to increase the productivity of milk and to enhance the immunity and the like as well as to prevent and treat the symptoms by the abnormal fermentation of enteric pathogens since it sustains the intestinal flora stably.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003247193A AU2003247193A1 (en) | 2003-07-23 | 2003-07-23 | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
PCT/KR2003/001461 WO2005007834A1 (en) | 2003-07-23 | 2003-07-23 | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2003/001461 WO2005007834A1 (en) | 2003-07-23 | 2003-07-23 | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007834A1 true WO2005007834A1 (en) | 2005-01-27 |
Family
ID=34074810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2003/001461 WO2005007834A1 (en) | 2003-07-23 | 2003-07-23 | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003247193A1 (en) |
WO (1) | WO2005007834A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007040445A1 (en) * | 2005-10-06 | 2007-04-12 | Probi Ab | Use of lactobacillus for treatment of virus infections |
WO2012013862A1 (en) * | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status |
GB2484126A (en) * | 2010-09-30 | 2012-04-04 | Univ Plymouth | Foodstuff fermented with lactic acid producing bacteria |
CN101384269B (en) * | 2005-10-06 | 2012-11-14 | 普罗比公司 | Use of lactobacillus for treatment of virus infections |
WO2013008039A3 (en) * | 2011-07-14 | 2013-03-21 | Gt Biologics Ltd | Bacterial strains isolated from pigs |
WO2014140115A1 (en) * | 2013-03-14 | 2014-09-18 | Nestec S.A. | Lactobacillus plantarum ncc 2936 and food preservation |
US10179153B2 (en) | 2014-10-21 | 2019-01-15 | Universidad De Leon | Probiotic and prebiotic compositions |
CN109385387A (en) * | 2018-12-28 | 2019-02-26 | 上海源耀生物股份有限公司 | The lactobacillus reuteri of anti-TGEV a kind of and its application |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
CN110997898A (en) * | 2018-07-13 | 2020-04-10 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP17 strain and use thereof |
CN111032857A (en) * | 2018-07-13 | 2020-04-17 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP243 strain and use thereof |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
CN113151045A (en) * | 2011-06-10 | 2021-07-23 | 株式会社爱茉莉太平洋 | Novel lactobacillus plantarum isolated from tea tree leaves |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
WO2022180077A1 (en) * | 2021-02-24 | 2022-09-01 | Belano Medical Ag | Agent for binding and displacing corona viruses on living cells and on surfaces |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
CN116790403A (en) * | 2023-02-19 | 2023-09-22 | 浙江大学 | Composite probiotics for improving pork quality and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0955061A1 (en) * | 1998-03-20 | 1999-11-10 | Medipharm CZ, s.r.o. | Oral product for the prevention and therapy of porcine gastroenteric infections |
-
2003
- 2003-07-23 WO PCT/KR2003/001461 patent/WO2005007834A1/en active Application Filing
- 2003-07-23 AU AU2003247193A patent/AU2003247193A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0955061A1 (en) * | 1998-03-20 | 1999-11-10 | Medipharm CZ, s.r.o. | Oral product for the prevention and therapy of porcine gastroenteric infections |
Non-Patent Citations (2)
Title |
---|
MICHAIL, S.: "Lactobacillus plantarum reduces in vitro the secretory response of intestinal epithelial cells to enteropathogenic E.coli infection", J PEDRIATR GASTROENTEROL NUTR., vol. 35, no. 3, September 2002 (2002-09-01), pages 350 - 355, XP009176032, DOI: doi:10.1097/01.MPG.0000025389.13337.3F * |
SUMA, K.: "Plantaricin LP84, a broad spectrum heat-stable bacteriocin of Lactobacillus plantarum NCIM 2084 produced in a simple glucose broth medium", INT J FOOD MICROBIOL., vol. 40, no. 1-2, 3 March 1998 (1998-03-03), pages 17 - 25 * |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007040445A1 (en) * | 2005-10-06 | 2007-04-12 | Probi Ab | Use of lactobacillus for treatment of virus infections |
AU2006297895B2 (en) * | 2005-10-06 | 2011-09-01 | Probi Ab | Use of lactobacillus for treatment of virus infections |
CN101384269B (en) * | 2005-10-06 | 2012-11-14 | 普罗比公司 | Use of lactobacillus for treatment of virus infections |
US8420376B2 (en) | 2005-10-06 | 2013-04-16 | Probi Ab | Use of Lactobacillus for treatment of virus infections |
US8691214B2 (en) | 2005-10-06 | 2014-04-08 | Probi Ab | Use of Lactobacillus for treatment of virus infections |
WO2012013862A1 (en) * | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status |
GB2484126A (en) * | 2010-09-30 | 2012-04-04 | Univ Plymouth | Foodstuff fermented with lactic acid producing bacteria |
WO2012042223A2 (en) | 2010-09-30 | 2012-04-05 | University Of Plymouth | Fermented foodstuff |
CN113151045A (en) * | 2011-06-10 | 2021-07-23 | 株式会社爱茉莉太平洋 | Novel lactobacillus plantarum isolated from tea tree leaves |
CN104080903B (en) * | 2011-07-14 | 2018-06-22 | 4D制药研究有限公司 | The bacterial strain detached from pig |
WO2013008039A3 (en) * | 2011-07-14 | 2013-03-21 | Gt Biologics Ltd | Bacterial strains isolated from pigs |
US9539293B2 (en) | 2011-07-14 | 2017-01-10 | 4D Pharma Research Limited | Porcine lactic acid bacterial strains |
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
CN104080903A (en) * | 2011-07-14 | 2014-10-01 | Gt生物制剂有限公司 | Bacterial strains isolated from pigs |
US10183046B2 (en) | 2011-07-14 | 2019-01-22 | 4D Pharma Research Limited | Porcine lactic acid bacterial strains |
RU2677890C2 (en) * | 2011-07-14 | 2019-01-22 | 4Д Фарма Рисерч Лимитед | Bacterial strains isolated from pigs |
CN109777746A (en) * | 2011-07-14 | 2019-05-21 | 4D制药研究有限公司 | The bacterial strain separated from pig |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
WO2014140115A1 (en) * | 2013-03-14 | 2014-09-18 | Nestec S.A. | Lactobacillus plantarum ncc 2936 and food preservation |
US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
EP3209307B1 (en) * | 2014-10-21 | 2022-10-05 | Aquilon Cyl Sociedad Limitada | Probiotic and prebiotic compositions |
US10179153B2 (en) | 2014-10-21 | 2019-01-15 | Universidad De Leon | Probiotic and prebiotic compositions |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
CN111032857A (en) * | 2018-07-13 | 2020-04-17 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP243 strain and use thereof |
CN110997898A (en) * | 2018-07-13 | 2020-04-10 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP17 strain and use thereof |
CN110997898B (en) * | 2018-07-13 | 2023-10-24 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP17 strain and application thereof |
CN111032857B (en) * | 2018-07-13 | 2023-10-24 | Cj第一制糖株式会社 | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP243 strain and application thereof |
CN109385387A (en) * | 2018-12-28 | 2019-02-26 | 上海源耀生物股份有限公司 | The lactobacillus reuteri of anti-TGEV a kind of and its application |
CN109385387B (en) * | 2018-12-28 | 2022-04-05 | 上海源耀农牧科技有限公司 | TGEV-resistant lactobacillus reuteri and application thereof |
WO2022180077A1 (en) * | 2021-02-24 | 2022-09-01 | Belano Medical Ag | Agent for binding and displacing corona viruses on living cells and on surfaces |
CN116790403A (en) * | 2023-02-19 | 2023-09-22 | 浙江大学 | Composite probiotics for improving pork quality and application thereof |
CN116790403B (en) * | 2023-02-19 | 2024-03-15 | 浙江大学 | Composite probiotics for improving pork quality and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2003247193A1 (en) | 2005-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005007834A1 (en) | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus | |
Rajoka et al. | Isolation and evaluation of probiotic potential of lactic acid bacteria isolated from poultry intestine | |
CN106282072B (en) | Compound lactobacillus microecological preparation and preparation method and application thereof | |
US7192581B2 (en) | Lactobacillus reuteri useful as probiotics | |
CN109749957B (en) | Preparation and application of lactobacillus gasseri preparation with aquatic pathogenic bacteria antagonistic property | |
Argañaraz-Martínez et al. | Physiological and functional characteristics of Propionibacterium strains of the poultry microbiota and relevance for the development of probiotic products | |
WO2023087944A1 (en) | Pediococcus acidilactici for improving production performance and immune level of broilers, and screening method therefor and use thereof | |
CN113080309B (en) | Bacillus subtilis with antibacterial and antiviral functions and application thereof | |
CN113170842A (en) | Composite microecological preparation for preventing and treating necrotic enteritis of poultry and application thereof | |
CN113621533A (en) | Streptomyces rubiginosus Z1-26, microecological preparation and preparation method thereof | |
Rapsang et al. | Identification of Lactobacillus pobuzihii from tungtap: a traditionally fermented fish food, and analysis of its bacteriocinogenic potential | |
Wulandari et al. | Quality and probiotic lactic acid bacteria diversity of rabbit meat Bekasam-fermented meat | |
KR100585391B1 (en) | Acid tolerant probiotic Lactobacillus plantarum Probio-38 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus | |
KR100557397B1 (en) | Acid tolerant probiotic Lactobacillus reuteri Probio-054 that can suppresses the growth of pathogenic microorganisms | |
KR100962179B1 (en) | A new Lactobacillus reuteri HY 25101 with inhibitory activity against porcine epidemic diarrhea virus and A Feed additive containing thereof | |
KR101098946B1 (en) | A compound for feed additive comprising novel Lactobacillus salivarius G1-1 | |
KR101201420B1 (en) | A feed additive containing novel Lactobacillus jonhsonnii | |
KR100513168B1 (en) | Acid tolerant probiotic Enterococcus faecalis Probio-056 that can suppresses the growth of pathogenic microorganisms and PED coronavirus | |
CN109423467B (en) | Lactobacillus plantarum and application thereof in fields of food and feed | |
KR101201337B1 (en) | A feed additive containig novel Lactobacillus spp. complex | |
KR100585392B1 (en) | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus | |
KR100513167B1 (en) | Acid tolerant probiotic Enterococcus faecalis Probio-053 that can suppresses the growth of pathogenic microorganisms and Salmonella gallinarum | |
Lavanya et al. | Isolation and characterization of probiotic bacteria from the soil samples of the coastal areas of (Gudur division, Nellore Dt.) for utilization in Shrimp farming | |
KR100523255B1 (en) | Acid tolerant probiotic Enterococcus faecium Probio-048 that can suppresses the growth of pathogenic microorganisms and Salmonella gallinarum | |
KR20050041808A (en) | Leuconostoc citreum km20 that can suppress the growth of pathogenic microorganisms and suppressed tumour growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |